Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 9Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 7Glioblastoma 7Colorectal Neoplasms 6Gliosarcoma 5Neoplasm Metastasis 4Colonic Neoplasms 4Breast Neoplasms 4Brain Neoplasms 4Rectal Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Advanced Solid Tumor 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solitary Fibrous Tumor, Pleural 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Mesothelioma, Malignant 2Melanoma 2Leukemia, Myeloid, Acute 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Astrocytoma 2Waldenstrom Macroglobulinemia 1

Interventions

Irinotecan 2vistusertib 1sapanisertib 1durvalumab 1danvatirsen 1ceralasertib 1cediranib 1ZD4054 1Topotecan 1HM781-36B 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 13-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Solid Malignancies × cediranib × Clear all
NCT00981721 2011-06-20

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

AstraZeneca

Phase 1 Completed
20 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡